Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
Four Western life science investors are entering a licensing deal with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals for $400 million, an indication of the growing trend of out-licensing deals by Chinese biotech firms, Biopharma Drive reported.
A Subscription is Required to Access this Content
Subscribe to China Law & Practice today for:
Already a Subscriber? Log In Here
Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)
